The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | Potential clinical applications of CXCR4 antagonists in cancer
Lilach Moyal, PhD, Tel Aviv University, Tel Aviv, Israel, discusses potential applications of CXCR4 inhibitors and outlines the benefits of using CXCR4 as a therapeutic target for mycosis fungoides (MF). Whilst CXCR4 antagonists are approved by the FDA for stem cell mobilization, they have been found to induce apoptosis of malignant cells through inhibition of downstream signaling cascades involved in cell survival. Therefore, several ongoing pre-clinical and clinical trials are investigating CXCR4 antagonists in combination with other agents and as a monotherapy in solid tumors. Dr Moyal explains that CXCR4 inhibition strategies might be more efficient in MF than in other tumors because it can be used as a localized skin-directed treatment. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
